Your English writing platform
Free sign upSuggestions(1)
Exact(3)
At 24 weeks, 14/25 patients (56%) with baseline JAK2V617F mutation achieved a spleen response.
Forty-four percent of CML patients with the BCR-ABL T315I mutation achieved a response, and responses were reported as durable.
In that study using tumour response according to Miller Payne criteria as a surrogate end point for outcome, 2/2 TNBC patients with a BRCA1 mutation achieved a pathological complete remission (pCR) on conventionally dosed cisplatin [ 37].
Similar(57)
Patients with PIK3CA mutations achieved a median PFS of 2.3 month and a median OS of 5.8 months compared to 4.6 and 9.2 months, respectively, in patients who did not carry these mutations.
Finally, a third patient (pt 21) with a KRAS mutation achieved long-lasting stable disease (8 months), under cetuximab-irinotecan treatment.
By this analysis, mutation profiling achieved a similarly high specificity of 99.8%.
Although CHEK2 H371Y carriers were more likely to respond to neoadjuvant chemotherapy, only small subset of mutation carriers achieved a pCR, the majority of CHEK2 H371Y carriers who did not reach a pCR might have a particularly aggressive phenotype.
Four patients (three imatinib resistant, two of whom carried the known imatinib-resistance mutation, M351T) achieved a major cytogenetic response, which corresponded with 1- or 2-log reductions in BCR-ABL transcript levels, and an overall 32% median reduction in BCR-ABL transcripts after 4 weeks of treatment.
All other patients with biopsies performed 2 to 17 months prior to treatment had additional alterations of known significance, except for one individual (case #1) who had only a BRAF mutation and achieved a CR that is ongoing at 28.7+ months.
In a phase I trial of single agent MK4827 enriched with patients having BRCA1 or BRCA2 mutations, 6 patients, including 5 with BRCA mutation, achieved PR.
Another finding in this study which is noteworthy, is 1 patient who had BRAF mutation achieved PR.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.
Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com